News & Events
- Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
- Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
- Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
- Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
- Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020
- Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer
- Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting
- Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020
- Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients
- Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
- Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. as Chief Medical Officer
- Seres Therapeutics to Present at Upcoming Investor Conferences
- Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results
- Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock
- Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock